
Med Dir-Cardiology Med Affairs - HTN. DIY Maker on insta @SaplingMakerLab. Tweets/retweets=my own and not endorsed by my employer, Kardigan.
Portland, OR
Joined October 2013
- Tweets1.5K
- Following1.1K
- Followers431
- Likes3.7K
Jon Ward retweeted
Amid everything else that was going on, pictured here are a bunch of the UO athletic training staff who devote their professional lives to these guys, through mundane daily treatment to trauma situations like this. Shoutout to them all for their expertise and devotion. #GoDucks
Visit our YouTube channel to learn more about the five risk factors for cardiovascular disease and strategies for blood-pressure control to reduce morbidity and mortality. nej.md/4uZTJGC
Jon Ward retweeted
Among the Veterans' Health Administration (VHA), Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation improves calibration and discrimination and can accurately predict 10-year ASCVD risk among Veterans ahajrnls.org/4oCQn9f
It would be interesting to see what the same analysis would result in different subgroups, such as renal patients and/or hypertensive patients.
SGLT2s Best ARNIs in Frail, Older Adults With HFpEF medscape.com/viewarticle/sgl…
1
79
Jon Ward retweeted
$NTLA News: Intellia announces positive longer-term data from the ongoing Phase 1 trial in #ATTRamyloidosis with polyneuropathy and the company’s latest publication in @NEJM. Read the press release: ir.intelliatx.com/news-relea…
Jon Ward retweeted
Cardio Town Hall: Amyloidosis is June 12, get prepared with NEW CardioBites+: Amyloidosis to learn the different mechanisms of disease and why understanding these differences may impact management decisions for these patients.
13-minute watch >> youtu.be/Fzq7DPIlg_A
Jon Ward retweeted
The Multi-Ethnic Study - MESA -
🤔"Group 1
LDL-C, mg/dL (SD) : 82.8 (14.6)
Lp(a), mg/dL (IQR): 11.1 (5.1–22.2)"
🤔"Group 2
LDL-C, mg/dL (SD) : 131.5 (23.1)
Lp(a), mg/dL (IQR): 14.3 (7.4–25.6)"
👉"Group 3: LDL-C≤100, Lp(a) ≥ 50"
👉"Group 4: LDL-C > 100, Lp(a) ≥ 50"
Jon Ward retweeted
Knowledge is power, especially for your heart!🫀 Lipoprotein(a) [Lp(a)] is a genetic risk factor for heart disease & stroke. Identifying high Lp(a) levels early can help individuals take proactive steps to protect their #hearthealth.
📃Learn more: learnyourlipids.com/lipid-di…
Jon Ward retweeted
Just published: 🫀Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies🔬
🚨 New insights from Palanisamy, Burka & Blaha (2025) show Lp(a) & CAC aren’t just independent risk factors—they amplify each other! CAC exposes hidden atherosclerosis, while Lp(a) fuels thrombotic risk, making them essential first-line tests for primary prevention.
With Lp(a)-lowering therapies emerging, their role in high-CAC patients needs urgent study. Is CAC-guided Lp(a) therapy the future? #CVprev @foundationofnla @Heart_SCCT @MichaelJBlaha @rblument1 @PalanisamySri @SBurkaMD
📖 Read more: doi.org/10.1007/s11886-025-0…
This picture is so profound. With 10 years of working in the ICU, there were several times when it felt like just because we can doesn’t mean we should. As one nurse put it “you’re slapping back the hand of Jesus” - the crocs are a nice added touch to the picture BTW
Jon Ward retweeted
In our new study in EJPC, optimal CVD risk factor control was a/w lower risk across Lp(a) levels, though residual risk remains. These results show the importance of aggressive risk factor mgmt in patients with elevated Lp(a). @AlexRazavi @Lpa_Doc
academic.oup.com/eurjpc/adva…
Jon Ward retweeted
#AHA24 ICYMI: #JACC AE Dr. @MarcBonaca and Dr. @Lpa_Doc discuss new insights from the MESA cohort about OxPL-apoB and risk for calcific aortic valve disease 👇
📄: bit.ly/3YRMeDf
Jon Ward retweeted
#AHA24: How does OxPL-apoB affect the risk of calcific aortic valve disease? Using data from MESA, Drs. @hsbhatia, @Lpa_Doc & team show that ⬆️ OxPL-apoB is associated with increased incidence and progression of valve disease bit.ly/3YRMeDf #JACC
Jon Ward retweeted
Lipoprotein, Lp(a) and LDL-cholesterol, LDL-C, are independent and additive for cardiovascular risk. Reduction in LDL-C cannot fully offset Lp(a)-mediated risk suggesting a need for targeted therapy for both. @PeterWilleit @hsbhatia @Lpa_doc ahajournals.org/doi/abs/10.1…
Jon Ward retweeted
"This is why you come to Oregon."
#GoDucks
Jon Ward retweeted
An estimated 1.19 million deaths per year could be prevented with optimal implementation of GDMT for heart failure with reduced ejection fraction globally. @GCFMD
ja.ma/3NaKb7C
Jon Ward retweeted
Our new expert consensus document justifies why Indian and other South Asian patients at extreme ASCVD risk need to have LDL-C targets of 30 mg/dl and even lower to 10-15 mg/dl in those still suffering recurrent events.
Lipid Association of India's latest publication in JAPI "Does Adopting Western Low-density Lipoprotein Cholesterol Targets Increase Cardiovascular Events in Indians? Expert Opinion From the Lipid Association of India" is a must- read. japi.org/article/japi-72-10-… @DineshKalra
Jon Ward retweeted
Higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. ja.ma/3BoACQ5
Jon Ward retweeted
Here is a paper on heart failure linking Lp(a) and @OxPL_apoB to outcomes. This may be mediated via a lncRNA that induces myocardial fibrosis.
More to come on this story. @JJheart_doc @pnatarajanmd ncbi.nlm.nih.gov/pubmed/3886…
Interesting paper.
"Exercise-Induced Increases in Oxidized Low-Density Lipoprotein Are Associated with Adverse Outcomes in Chronic Heart Failure"
doi.org/10.1016/j.cardfail.2…
However, they unfortunately use the Mercodia assay, which doesn't distinguish between oxLDL and LDL, despite what the label says.
Hence they find, "The oxLDL/LDL-c ratio did not change in either group (Table 2)." No, it wouldn't.
People with HF whose LDL goes up on exercise are much more likely to have a bad outcome.
"Subjects with an absolute increase in oxLDL more than 11.0 U/L were at significantly higher risk of meeting the combined end point of VAD, heart transplantation, or death (unadjusted hazard ratio 8.6...; this remained significant when adjusted for peak VO2, LVEF, NYHA class, sex, and age (hazard ratio 46.6..."
I'd love to see this redone using the OxPL/ApoB assay...
@Lpa_Doc @realDaveFeldman #lcl6
Ready to travel, but no place to go. Thank you to @HFSA for making the difficult but right decision. @robmentz @dranulala there should be a picture collage of everyone wearing their purples!































